

DAFTAR PUSTAKA

- American Cancer Society. Breast Cancer Facts & Figures 2015-2016. Atlanta: American Cancer Society, Inc. 2015.
- American Cancer Society. (2016). Breast Cancer What is breast cancer? *American Cancer Society*.
- Asnaghi L., Bruno P., Priulla M., Nicolin A. (2004). mTOR: a protein kinase switching between life and death. *Pharmacol. Res.* 50 545–549.
- Boenisch T., Kumar G.L., Rudbeck L. (2009). *Immunohistochemical Staining Method*. Fifth Edition. Dako North America: California.
- Cao, G., Xu, X., Zhang, J., Chen, B., & Xiong, M. (2016). Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer. *PLoS ONE*. 11(12), e0168085.
- Chen, N., & Karantza-Wadsworth, V. (2009). Role and regulation of autophagy in cancer. *Biochimica et Biophysica Acta*. 1793(9), 1516–1523.
- Coleman J. F. (2010). *Robbins and Cotran's Pathologic Basis of Disease. The American Journal of Surgical Pathology* (Vol. 34).
- Deng L., Chen J., Zhong X. R., Luo T., Wang Y. P., Huang H. F., Zheng H. (2015). Correlation between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women. *PLoS ONE*. 10(3), e0120511.
- Ding, X.-F., Li, L.-F., Zhou, X.-L., Guo, L.-N., Dou, M.-M., Chi, Y.-Y., Sun, T.-W. (2017). P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. *PLoS ONE*. 12(1), e0170302.
- Duraiyan J., Govindarajan R., Kaliyappan K., Palanisamy M. (2012). Application of immunohistochemistry, *J Pharm Bioall Sci.* 4 : 307-9.
- Edge S., Byrd D., Compton C. (2010). Breast. *AJCC Cancer Staging Manual*, 347–376.
- Elizia A., Marques M., Elias S. T. (2016). mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis. *J Oral Pathol Med.* 319–328.

- Glick D., Barth S., Macleod K. F. (2010). Autophagy: cellular and molecular mechanisms. *J. Pathol.* 221 3–12
- Guertin D. A., Sabatini D. M. (2007). Defining the Role of mTOR in Cancer. *Cancer Cell.* 12(1), 9–22.
- Hiramanek, N. (2004). Breast cancer recurrence: follow up after treatment for primary breast cancer. *Postgrad Med J.* 80(941), 172–176.
- Jung C. H., Ro S.-H., Cao J., Otto N. M., Kim D.-H.(2010). MTOR regulation of autophagy. *FEBS Letters.* 584(7):1287–1295.
- Kim M., Kim T., Sung C. O., Choi C. H., Lee J., Kim B., Bae D. (2010). High expression of mTOR is associated with radiation resistance in cervical cancer. *J Gynecol Oncol.* 21(3), 181–185.
- Kumar V., Abbas A. K., Aster J. C. (2013). *Endocrine system. Robbins Basic Pathology.*
- Lee J. J., Loh K., Yap Y.S. (2015). PI3K/Akt/mTOR inhibitors in breast cancer. *Cancer Biol Med.* 12(4), 342–54.
- Li S., Wang Z., Huang J., Cheng S., Du H., Che G., Peng Y. (2016). Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis. *BMC Cancer.* (37).
- Mathew R, Karantza-Wadsworth V, White E. (2007). Role of autophagy in cancer. *Nat Rev Cancer.* 7:961–967.
- Metcalfé Kelly, Gershman Shelley, Ghadirian Parviz, Lynch Henry T, Snyder Carrie, Tung Nadine et al (2014). Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis *BMJ*; 348:g226
- Moore K. L., Daley A. F., Agur A. M., Moore M. E. (2013). *Anatomi Berorientasi Klinis* (5thed). Jakarta: Erlangga.
- Mutee A. F., Kaur G., Kumar G., Sifzizul T., Muhammad T., Khalid I. A., Lan Tan M. (2009). Immunohistochemical Evaluation of mTOR and Beclin-1 Protein Expression in Human Breast Cancer and Adjacent Normal Tissues, A Study in Malaysian Patients. *Bentham Op.* 3, 111–117.
- Ojha R, Bhattacharyya S, Singh SK (2015). Autophagy in cancer stem cells: a potential link between chemoresistance, recurrence, and metastasis. *Biores Open Access.* 4:1, 97–108

Panduan Penatalaksanaan Kanker Payudara. (2014). Pedoman Penatalaksanaan Kanker Solid. PERABOI.

Pattingre S., Espert L., Biard-Piechaczyk M., Codogno P. (2008). Regulation of macroautophagy by mTOR and Beclin 1 complexes. *Biochimie*. 90(2), 313–323.

Philipp L, Griniak K, Felder S, Pape FU, Manfred D (2014) Immunohistochemical Analysis of mTOR Pathway Expression in Gastric Neuroendocrine Tumors. *J Clin Exp Pathol*. 4: 173.

Walsh S., Flanagan L., Quinn C., Evoy D., Mcdermott E. W., Pierce A., Duffy M. J. (2012). mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors. *The Breast*. 21(2), 178–182.

Wang H. G. (2003). Autophagy and Cancer. 1st ed. New York: Springer.

White E. (2015). The role for autophagy in cancer. *J Clin Invest*. 125(1):42-46.

Wu S., Sun C., Tian D., Li Y., Gao X., He S., Li T. (2015). Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer. *Int J Clin Exp Pathol*. 8(4), 3882–3891.

Yang Z., Chee C., Huang S., Sinicrope F. (2011). The role of autophagy in cancer: therapeutic implications. *Mol Cancer Therap*. 1533–1541.

Youliden D. R., Cramb S. M., Yip C. H., Baade P. D. (2014). Incidence and Mortality of Female Breast Cancer in the Asia-Pacific Region. *Cancer Biol Med*. 11(2), 101–15.

Zhang S.-J., Yang W., Wang C., He W. S., Deng H.-Y., Yan Y.G., Wang W.J. (2016). Autophagy: A double-edged sword in intervertebral disk degeneration. *Clinica Chimica Acta*. 457, 27–35.